Evidence map›Paper›PMID 37688505›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2023

Muhammad Usman Tareen, Sana Riaz, Saima Shakil Malik, Sana Zahid, Anum Khursheed, Fizza Tariq, Faiza Abbas, Muhammad Nouman Malik, Riffat Aysha Anis, Mariam Anees and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Muhammad Usman TareenDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Sana RiazDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Saima Shakil MalikDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Sana ZahidAlpha Genomics Private Limited, Islamabad 45710, Pakistan.
Anum KhursheedDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Fizza TariqDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Faiza AbbasDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Muhammad Nouman MalikDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Riffat Aysha AnisInstitute of Diet & Nutritional Sciences, The University of Lahore, Islamabad 54000, Pakistan.
Mariam AneesDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Iram MurtazaDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.ORCID 0000-0001-8092-5211
Aneesa SultanDepartment of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.ORCID 0000-0002-7017-815X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) continues to be the most common cancer in the women worldwide. Since estrogen receptor (ER)-positive BC accounts for the majority of newly diagnosed cases, endocrine therapy is advised to utilize either tamoxifen (Tam) or aromatase inhibitors. The use of Tam as a monotherapy or in conjunction with an aromatase inhibitor following two or three years of endocrine therapy has long been recommended. When used adjuvantly, Tam medication reduces BC mortality and relapses, while it extends survival times in metastatic BC when used in conjunction with other treatments. Unfortunately, the efficiency of Tam varies considerably. This study was conducted to explore the influence of genetic polymorphisms in

Indexed as

Breast NeoplasmsCytochrome P-450 CYP2C19TamoxifenAntineoplastic Agents, HormonalEstrogensFemaleHumansPakistanSouth Asian PeopleafimoxifeneAntineoplastic Agents, HormonalCYP2C19 protein, humanCytochrome P-450 CYP2C19EstrogensTamoxifenCYP2C19cytochrome p450ER-positive breast cancerpersonalized medicinepharmacogenomicsTamoxifen

Identifiers

PMID37688505
PMCPMC10666731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.